The EPS miss may pressure the stock near-term, but the ongoing strategic review and restructuring progress provide upside optionality. Monitor for updates on the sale process and Q2 2026 operating expense reductions.
Price Chart
Executive Summary
Theravance Biopharma reported Q1 2026 revenue of $17.7M (+15% YoY), slightly above the $17.4M consensus, but GAAP EPS of -$0.10 missed the Street estimate of -$0.05. Net loss improved to -$4.9M from -$13.6M a year ago, and non-GAAP net income turned positive at $0.6M. The company reaffirmed its restructuring and cost-cutting targets, while the strategic review for a potential sale continues.
Key Financial Metrics
Key Facts
- Total revenue $17.7M, up 15% YoY from $15.4M, entirely from Viatris collaboration
- GAAP net loss per share -$0.10 vs. consensus -$0.05 (100% miss)
- Net loss narrowed to $4.9M from $13.6M in Q1 2025
- Non-GAAP net income from operations was $0.6M vs. -$8.6M last year
- Cash & marketable securities $394.7M as of March 31, 2026, no debt
- Operating expenses (excl. restructuring) down ~20% YoY; restructuring on track for $60-70M annualized cash flow by Q3 2026
- Strategic Review Committee actively evaluating options including a sale
Financial Impact
EPS miss of $0.05 vs. consensus, revenue beat of $0.3M; net loss improvement of $8.7M YoY is overshadowed by the EPS shortfall
Risk Factors
- Strategic review may not result in a transaction or may be delayed
- Failure to achieve $100M TRELEGY milestone if GSK sales fall below $3.5B
- Execution risk in achieving full restructuring savings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-056733 |
| Document: tm2613884d1_8k.htm | 0001104659-26-056733 |
| Document: 0001104659-26-056733-index-headers.html | 0001104659-26-056733 |
| Document: 0001104659-26-056733-index.html | 0001104659-26-056733 |
| Document: 0001104659-26-056733.txt | 0001104659-26-056733 |
| 8-K Data (Synthetic) | 0001104659-26-056733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | DEFA14A | $17.03 $17.03 | · 0.00% | ▼ −0.23% | — |
Aug 21, 2026 6w ago | DEFM14A | $17.01 $17.05 | ▲ +0.24% | ▲ +0.76% | — |
Aug 11, 2026 7w ago | PREM14A | $16.91 $17.06 | ▲ +0.89% | ▲ +1.95% | — |
Aug 10, 2026 7w ago | 8-K | $16.91 $17.06 | ▲ +0.89% | ▲ +1.80% | — |
Jun 29, 2026 13w ago | 8-K | $17.06 $16.86 | ▼ −1.17% | ▼ −0.89% | — |
Jun 23, 2026 14w ago | 8-K | $17.27 $16.81 | ▼ −2.66% | ▼ −4.60% | — |
May 7, 2026 21w ago | 8-K | $17.02 $15.92 | ▼ −6.46% | ▼ −9.60% | — |
Mar 3, 2026 30w ago | 8-K | $13.96 $16.23 | ▼ −16.26% | ▼ −20.66% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access